Bristol’s 2026 Revenue Buoyed By Eliquis Ahead Of Ex-US Generic Entries In 2027

Growth Portfolio Performance Drove Q4 2026 Gains

 
• By Mandy Jackson
  
BMS aims to grow its anticoagulant portfolio beyond Eliquis with milvexian (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business